Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency

Oncology·MeSH: Mucopolysaccharidosis I

Prevalence

5.0 / 100K

0 drugs in development·0 companies·2 clinical trials

Frequently asked questions

How many clinical trials target Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency?

There are 2 clinical trials targeting Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency tracked by BioSniper.

What is the prevalence of Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency?

The estimated prevalence of Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency is approximately 5.0 per 100,000 population.

Deep-dive into Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency — Drugs in Development & Clinical Trials | BioSniper